NAD is typically used in laboratory research through multiple experimental approaches, each with distinct dosing parameters. In in vitro studies, researchers typically work with NAD concentrations ranging from 1–100 μM in cell-based assays to investigate enzyme activity, redox reactions, and metabolic readouts. Meanwhile, preclinical animal studies show that NAD is generally administered at doses dependent on the research model and route of administration. Direct NAD administration in animal models uses varying doses (typically 10–300 mg/kg), while NAD precursor compounds follow different protocols. NAD Precursor Studies (NR and NMN): Clinical research on NAD precursors reports distinct dosage ranges: Nicotinamide Riboside (NR): 100–1000 mg daily, with most studies using 250–500 mg per day Nicotinamide Mononucleotide (NMN): 150–1200 mg daily, with studies showing efficacy at 250–900 mg per day Moreover, key observations from these research contexts include: Activation of NAD -dependent enzyme systems: Sirtuins and PARPs show increased activity with adequate NAD substrate availability Improvements in mitochondrial function markers: Studies report associations between NAD availability and oxidative phosphorylation capacity Shifts in gene expression profiles: Transcriptomic analyses describe differential expression patterns in NAD -modulated experimental conditions These findings remain within controlled experimental settings and are presented as research observations rather than clinical outcomes.
